Catherine Zimel
Overview
Explore the profile of Catherine Zimel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
129
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosen E, Won H, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al.
Nat Commun
. 2022 Apr;
13(1):1936.
PMID: 35383193
No abstract available.
2.
Rosen E, Won H, Zheng Y, Cocco E, Selcuklu D, Gong Y, et al.
Nat Commun
. 2022 Mar;
13(1):1450.
PMID: 35304457
The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-driven cancers, and we sought to characterize the molecular determinants of response and resistance. We find that...
3.
Rubinstein M, Hyman D, Caird I, Won H, Soldan K, Seier K, et al.
Cancer
. 2019 Dec;
126(6):1274-1282.
PMID: 31880826
Background: PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations...
4.
Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, et al.
Cancer Discov
. 2019 Dec;
10(2):198-213.
PMID: 31806627
mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or...